Evidence map›Paper›PMID 36838982›Full record

ArticleMolecules (Basel, Switzerland)2023

OAT3 Participates in Drug-Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8-A Metabolite of Bentysrepinine-In Rats and Humans In Vitro.

Aijie Zhang, Fanlong Yang, Yang Yuan, Cai Li, Xiaokui Huo, Jing Liu, Shenzhi Zhou, Wei Li, Na Zhang, Jianfeng Liu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Aijie ZhangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Fanlong YangKey Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China.
Yang YuanSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Cai LiSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Xiaokui HuoCollege of Pharmacy, Dalian Medical University, Dalian 116044, China.ORCID 0000-0003-4056-7987
Jing LiuHeping District Center for Disease Control and Prevention, Tianjin 300070, China.
Shenzhi ZhouWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Wei LiWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Na ZhangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jianfeng LiuKey Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China.
Shiqi DongKey Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China.
Huirong FanKey Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China.
Ying PengWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jiang ZhengWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shenyang Pharmaceutical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNTianjin University of Traditional Chinese Medicine · CNDalian Medical University · CN

Funding

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-042 and 2022-I2M-2-002the National Key R&D Program of China 2018YFC1708203the National Natural Science Foundation of China 82104284the Natural Science Foundation of Tianjin 20JCQNJC00320the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018PT35031
6 · The paper itself

Abstract

Bentysrepinine (Y101) is a novel phenylalanine dipeptide for the treatment of hepatitis B virus. Renal excretion played an important role in the elimination of Y101 and its metabolites, M8 and M9, in healthy Chinese subjects, although the molecular mechanisms of renal excretion and potential drug-drug interactions (DDIs) remain unclear. The present study aimed to determine the organic anion transporters (OATs) involved in the renal disposition of Y101 and to predict the potential DDI between Y101 and entecavir, the first-line agent against HBV and a substrate of OAT1/3. Pharmacokinetic studies and uptake assays using rat kidney slices, as well as hOAT1/3-HEK293 cells, were performed to evaluate potential DDI. The co-administration of probenecid (an inhibitor of OATs) significantly increased the plasma concentrations and area under the plasma concentration-time curves of M8 and M9 but not Y101, while reduced renal clearance and the cumulative urinary excretion of M8 were observed in rats. The time course of Y101 and M8 uptake via rat kidney slices was temperature-dependent. Moreover, the uptake of M8 was inhibited significantly by probenecid and benzylpenicillin, but not by

Indexed as

Organic Anion Transporters, Sodium-IndependentOrganic Anion Transport Protein 1AnimalsBenzamidesDipeptidesDrug InteractionsGuanineHEK293 CellsHumansKidneyProbenecidRatsRats, WistarBenzamidesDipeptidesentecavirGuanineN-(N-benzoyl-O-(2-dimethylaminoethyl)tyrosyl)phenylalaninolOrganic Anion Transporters, Sodium-IndependentOrganic Anion Transport Protein 1Probeneciddrug-drug interactionentecavirorganic anion transportersrenal excretionY101

Identifiers

PMID36838982
PMCPMC9967645
OpenAlexW4321458332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.